Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Dow
Fish and Richardson
Chubb
Johnson and Johnson
Argus Health
Federal Trade Commission
Novartis
Covington
McKesson

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,050,302

« Back to Dashboard

Which drugs does patent 9,050,302 protect, and when does it expire?

Patent 9,050,302 protects XYREM and is included in one NDA.

This patent has twelve patent family members in twelve countries.
Summary for Patent: 9,050,302
Title:Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
Inventor(s): Eller; Mark (Redwood City, CA)
Assignee: Jazz Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:13/837,714
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,050,302

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Jazz Pharms XYREM sodium oxybate SOLUTION;ORAL 021196-001 Jul 17, 2002 AA RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED. ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,050,302

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,772,306 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters ➤ Sign Up
8,952,029 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters ➤ Sign Up
9,486,426 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,050,302

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 201511752 ➤ Sign Up
Singapore 11201505029Q ➤ Sign Up
Mexico 2015011242 ➤ Sign Up
South Korea 20150125943 ➤ Sign Up
Japan 2016510031 ➤ Sign Up
Israel 240874 ➤ Sign Up
Hong Kong 1215539 ➤ Sign Up
European Patent Office 2961399 ➤ Sign Up
China 105073106 ➤ Sign Up
Canada 2902948 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Merck
Federal Trade Commission
Baxter
Healthtrust
AstraZeneca
Covington
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot